Search Results - "Lyrarakis G"

1112P Immunotherapy after progression to double immunotherapy: Pembrolizumab and Lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition.

Authors: Ziogas, D.C. Lyrarakis, G. Liontos, M. et al.

Source: Annals of Oncology. 2024 Supplement 2, Vol. 35, pS735-S736. 2p.

The role of the post-cardioversion time course of hs-CRP levels in clarifying the relationship between inflammation and persistence of atrial fibrillation.

Authors: Kallergis, E. M. Manios, E. G. Kanoupakis, E. M. et al.

Source: Heart. Feb2008, Vol. 94 Issue 2, p200-204. 5p. 2 Charts, 2 Graphs.

Indirect Comparison of the Efficacy of Pembrolizumab Versus Nivolumab as Adjuvant Options for Stage IIB/IIC Melanoma.

Authors: Andreikos DA Argyropoulou I Theocharopoulos C et al.

Source: Targeted oncology [Target Oncol] 2026 May; Vol. 21 (3), pp. 421-432. Date of Electronic Publication: 2026 May 08.

Publication Type: Journal Article; Comparative Study

Journal Info: Publisher: Springer-Verlag France Country of Publication: France NLM ID: 101270595 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1776-260X (Electronic) Linking ISSN: 17762596 NLM ISO Abbreviation: Target Oncol Subsets: MEDLINE

Toward Microbiome-Informed Melanoma Care: The Gut Microbiota in Melanoma Evolution, Immunotherapy Response and Immune-Related Toxicity.

Authors: Ziogas DC Theocharopoulos C Martinos A et al.

Source: Current oncology reports [Curr Oncol Rep] 2026 Feb 05; Vol. 28 (1), pp. 10. Date of Electronic Publication: 2026 Feb 05.

Publication Type: Journal Article; Review

Journal Info: Publisher: Current Science Country of Publication: United States NLM ID: 100888967 Publication Model: Electronic Cited Medium: Internet ISSN: 1534-6269 (Electronic) Linking ISSN: 15233790 NLM ISO Abbreviation: Curr Oncol Rep Subsets: MEDLINE

Transcriptomic signatures in peripheral CD4⁺T-lymphocytes may reflect melanoma staging and immunotherapy responsiveness prior to ICI initiation.

Authors: Palli E Lavigne M Verginis P et al.

Source: Frontiers in immunology [Front Immunol] 2025 Mar 28; Vol. 16, pp. 1529707. Date of Electronic Publication: 2025 Mar 28 (Print Publication: 2025).

Publication Type: Journal Article

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

Immunotherapy after progression to double immunotherapy: pembrolizumab and lenvatinib versus conventional chemotherapy for patients with metastatic melanoma after failure of PD-1/CTLA-4 inhibition.

Authors: Lyrarakis G Liontos M Anastasopoulou A et al.

Source: Frontiers in oncology [Front Oncol] 2024 Oct 07; Vol. 14, pp. 1420879. Date of Electronic Publication: 2024 Oct 07 (Print Publication: 2024).

Publication Type: Journal Article

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE

Bone mineral density changes following immune checkpoint inhibitor therapy: insights from a case series analysis.

Authors: Siampanopoulou V Ziogas DC Lyrarakis G et al.

Source: Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA [Osteoporos Int] 2025 Sep; Vol. 36 (9), pp. 1711-1718. Date of Electronic Publication: 2025 Aug 10.

Publication Type: Journal Article

Journal Info: Publisher: Springer International Country of Publication: England NLM ID: 9100105 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1433-2965 (Electronic) Linking ISSN: 0937941X NLM ISO Abbreviation: Osteoporos Int Subsets: MEDLINE

Reaching the Diagnosis of Checkpoint Inhibitor-Induced Diabetes Mellitus in Different Clinical Scenarios: A Real-World Application of Updated Diagnostic Criteria.

Authors: Angelousi A Ziogas DC Siampanopoulou V et al.

Source: Diseases (Basel, Switzerland) [Diseases] 2024 Feb 14; Vol. 12 (2). Date of Electronic Publication: 2024 Feb 14.

Publication Type: Case Reports; Journal Article

Journal Info: Publisher: MDPI AG Country of Publication: Switzerland NLM ID: 101636232 Publication Model: Electronic Cited Medium: Print ISSN: 2079-9721 (Print) Linking ISSN: 20799721 NLM ISO Abbreviation: Diseases Subsets: PubMed not MEDLINE

Exploring the Dynamics of Immune Checkpoint Inhibitor-Induced Eosinophilia in Advanced/Metastatic Melanoma: A Comprehensive Retrospective Analysis.

Authors: Diamantopoulos PT Gkoufa A Anastasopoulou A et al.

Source: Cancer medicine [Cancer Med] 2025 Apr; Vol. 14 (7), pp. e70679.

Publication Type: Journal Article

Journal Info: Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print Cited Medium: Internet ISSN: 2045-7634 (Electronic) Linking ISSN: 20457634 NLM ISO Abbreviation: Cancer Med Subsets: MEDLINE

Clinical benefit of immune checkpoint inhibitors in elderly cancer patients: Current evidence from immunosenescence pathophysiology to clinical trial results.

Authors: Ziogas DC Theocharopoulos C Aravantinou K et al.

Source: Critical reviews in oncology/hematology [Crit Rev Oncol Hematol] 2025 Apr; Vol. 208, pp. 104635. Date of Electronic Publication: 2025 Jan 30.

Publication Type: Journal Article; Review

Journal Info: Publisher: Elsevier Scientific Publishers Country of Publication: Netherlands NLM ID: 8916049 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0461 (Electronic) Linking ISSN: 10408428 NLM ISO Abbreviation: Crit Rev Oncol Hematol Subsets: MEDLINE